Surgical Room Supplies News
-
An Easy, Predictable, and Simpler Way to Embolize Tumors
Instylla is now enrolling patients in a clinical trial for the world’s first hydrogel-based liquid embolic intended for the treatment of hypervascular tumors. A second initial application for its Embrace embolic therapy is hemorrhage control, where the product offers advantages in terms of simplicity, speed, and safety. Amar Sawhney and his teams, it seems, can make medical hydrogels do ...
-
Palisade Bio And Newsoara Receive NMPA Clearance To Commence Phase 3 Clinical Trial In China Evaluating LB1148 To Accelerate The Return Of Bowel Function Following Abdominal Surgery
NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study Newsoara to fully fund Phase 3 program in China Under the Co-Development Agreement, commencement of Phase 3 program in China will trigger milestone payment to Palisade Bio Palisade Bio (Nasdaq: PALI), a clinical stage ...
By Palisade Bio
-
Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced The Extent And Severity Of Post-Surgical Intraabdominal Adhesions By 93%
Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery Company to Host Conference Call on Wednesday, March 16, 2022, at 8:30 a.m. EST Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) ...
By Palisade Bio
-
Palisade Bio (Nasdaq: PALI) To Present New Clinical Data Of LB1148 For Preventing Adhesions In Conjunction With Next Big Thing Session At Society Of American Gastrointestinal And Endoscopic Surgeons 2022 Annual Meeting
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was selected to present an ePoster entitled “Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148” at The Next ...
By Palisade Bio
-
Palisade Bio (NASDAQ: PALI) Adds Pharmaceutical Industry Executive Robert McRae To Leadership Team
Palisade Bio, Inc. (NASDAQ: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that Robert McRae has joined the senior management team as Senior Vice President, Operations and Strategic Development. Rob is an accomplished industry veteran with a proven track record of execution who will be responsible ...
By Palisade Bio
-
First Implants of PROPEL Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to offer the Company’s PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic ...
-
TISSIUM to present study results at the Hernia 2021 European Hernia Society - American Hernia Society Joint Congress
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, will present an e-poster on its research on a novel, atraumatic, and consistent hernia mesh fixation device at the Hernia 2021 European Hernia Society – American Hernia Society Joint Congress. The event is scheduled to be held virtually and in-person from October 13 – ...
By TISSIUM
-
CELLVIE featured in Biocentury`s Emerging Company Profile
Harvard spinout cellvie is pioneering therapeutic mitochondria transplantation as a way to rescue cell energy metabolism and save cells that would otherwise die. James McCully, a cellvie AG co-founder, developed the approach at Harvard Medical School to ameliorate ischemia-reperfusion injury, which is the tissue damage caused when the blood supply returns after a period of ischemia. "What Jim ...
By cellvie Inc.
-
TISSIUM to present study results at the 76th Annual Meeting of the American Society for Surgery of the Hand
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, has announced its research has been selected for presentation within the scientific program at the 76th Annual Meeting of the American Society for Surgery of the Hand. The event is scheduled to be held virtually and in-person from September 30 – October 2, 2021 in San Francisco, ...
By TISSIUM
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you